Literature DB >> 30366348

[Hip Osteoarthritis - Epidemiology and Current Medical Care Situation - Health Care Data of 2.4 Million AOK Baden-Württemberg Insurees Aged 40 Years or Older].

Heinz Endres1, Olaf Schneider2, Hanns-Peter Scharf3, Petra Kaufmann-Kolle4, Sabine Knapstein5, Christopher Hermann6, Burkhard Lembeck7, Johannes Flechtenmacher7,8.   

Abstract

BACKGROUND: Due to demographic changes an increasing number of hip osteoarthritis can be expected with corresponding effects on the health care system. Hence, the objectives of our study were to obtain substantiated evidence about current medical care situation of hip osteoarthritis patients including outpatient care situation and hip replacement surgery. PATIENTS AND METHODS: Overall, the medical care data of 2.4 million insurees of the AOK Baden-Württemberg for the years 2007 to 2016 were analyzed. Lower limit of age was 40 years. The data includes outpatient and inpatient healthcare claims.
RESULTS: The age standardized prevalence of hip osteoarthritis in adults aged 40 years or older is 6.18% (95% CI: ± 0.09%) among women and 6.02% (95% CI: ± 0.09%) among men. From the age of 75, sex differences become significant. The maximum number of newly diagnosed cases of hip osteoarthritis (women: 1.31%, men: 1.16%) is found in the 80 - 84-year-olds. From the age of 85, 17.4% of all women and 16.5% of all men show a hip osteoarthritis. The maximum number of hip replacement surgery among osteoarthritis patients (women: 5.2%, men: 4.3%) appears in the 75- to 79-year-olds. After the initial diagnosis of a hip osteoarthritis, every eighth (13.0%) AOK insured person receives a hip replacement surgery within the first year and one in four (24.8%) insurees within 8 years. Irrespective of the main diagnosis, numbers of hip replacement surgery did not increase between 2009 and 2016. On average, 300.9 (women) and 275.8 (men) hip replacement surgeries were performed per 100 000 insured years. From the age of 80, hip osteoarthritis drops back as the main diagnosis fur surgery. Consequently, from the age of 85 more than 70% of all hip replacement patients show a femoral fracture as main diagnosis. Only about ¾ of the hip osteoarthritis patients were in outpatient specialist care in the year before surgery, and far less than half of hip osteoarthritis patients received a referral to physiotherapy.
CONCLUSION: Osteoarthritis of the hip occurs approximately equally often in women and men up to the age of 75 years. Nevertheless, women underwent surgery more frequently. Overall, the number of hip replacement surgery has not increased in the last eight years. Within the first eight years after initial diagnosis of hip osteoarthritis 24.8% of all patients receive a hip TEP. Hence, the majority of patients is treated conservatively in the first eight years. A direct comparison between incidence and prevalent hip osteoarthritis patients reveals that after many years of therapeutic care in the last 1 - 2 years prior to surgery, both the specialist care as well as the referral to physiotherapy are reduced. A reassessment of conservative treatment options over time seems to be necessary. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2018        PMID: 30366348     DOI: 10.1055/a-0648-4945

Source DB:  PubMed          Journal:  Z Orthop Unfall        ISSN: 1864-6697            Impact factor:   0.923


  2 in total

1.  Evaluation of a collaborative ambulatory orthopedic care program for patients with hip and knee osteoarthritis: a comparative observational cohort study.

Authors:  Angelina Müller; Olga A Amberger; Anastasiya Glushan; Claudia Witte; Renate Klaaßen-Mielke; Burkhard Lembeck; Martin Beyer; Ferdinand M Gerlach; Kateryna Karimova
Journal:  BMC Musculoskelet Disord       Date:  2022-08-03       Impact factor: 2.562

2.  Indication for spinal surgery: associated factors and regional differences in Germany.

Authors:  Falko Tesch; Toni Lange; Patrik Dröge; Christian Günster; Johannes Flechtenmacher; Burkhard Lembeck; Bernd Kladny; Dieter Christian Wirtz; Fritz-Uwe Niethard; Jochen Schmitt
Journal:  BMC Health Serv Res       Date:  2022-09-01       Impact factor: 2.908

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.